Atriva Therapeutics GmbH

Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology

Atriva Therapeutics appoints Christian Pangratz as CEO, implementing planned management change

Atriva Therapeutics announces appointment of CSO and senior leaders to Clinical Development Team

Atriva Therapeutics announces Topline Results from the Proof of Concept (POC) / Phase 2a RESPIRE study (zapnometinib) in patients hospitalized with COVID-19

Atriva Therapeutics announces efficacy of its lead compound zapnometinib against Omicron

Atriva receives FDA Orphan Drug Designation for Zapnometinib to treat Hantavirus Infections

Atriva Therapeutics to take part in upcoming scientific and industry conferences in early 2022

Atriva Therapeutics strengthens advisory board with Piet Wigerinck

Atriva Therapeutics’ lead candidate Zapnometinib shows substantial efficacy against SARS-CoV-2

Atriva Therapeutics: Participation in upcoming scientific and industry conferences

Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding

Atriva Therapeutics kann dank Fördermitteln COVID-19-Medikament schneller entwickeln

Atriva Therapeutics Announces Changes to Management

Atriva Therapeutics Doses First Patient in Phase II RESPIRE trial in COVID-19

Atriva Therapeutics Announces Changes to Advisory Board

Atriva Therapeutics obtains approval from German authorities for Phase II trial in COVID-19 patients, led by Charité Clinic in Berlin

Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan

Publication in PNAS unveils molecular pathway required for influenza virus replication with large potential as an antiviral drug target

Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study

Atriva Therapeutics to take part in three major conferences in San Francisco, USA, in the upcoming week

Atriva Therapeutics Reports Results of ATR-002 Phase I Clinical Trial

Atriva Therapeutics Starts Clinical Development of Novel Host-Targeting Antiviral ATR-002 Against Influenza